Nurix Therapeutics stock tumbles on Sanofi program termination
Nurix Therapeutics (NRIX) fell 34% after Sanofi ended a Phase 1 trial for SAR448272, removing Nurix's eligibility for future milestone payments and royalties. Nurix retains rights to other programs and has $1.1B in cash to fund operations into 2029. The company has three clinical-stage programs in development.
How this was made
The 30-second read
Why it matters
The abrupt termination removes a key revenue source, prompting a sharp sell‑off.
Market read
NRIX shares fell 34% after‑hours as the partnership program was terminated, a material catalyst for the stock.
What to watch
The company retains other milestone‑eligible programs with Roche, Gilead and Sanofi, and has $1.1 bn cash runway through 2029.
Background
Sanofi ended development of SAR448272, an oral STAT6 degrader, ending NRIX's eligibility for related milestones.
Ticker impact
Sanofi terminated the Phase 1 trial of SAR448272, removing NRIX's eligibility for milestone payments and causing a 34% after‑hours drop.
likely continued pressure as investors reassess revenue outlook.
The termination eliminates future milestone and royalty streams, a material revenue component for NRIX.
Market effects
Highlights risk in biotech partnership models and may weigh on other protein‑degradation firms.
Primarily affects US‑listed biotech investors; limited broader market effect.
Limited to investors tracking clinical‑stage biotech collaborations.
Counterpoint
If NRIX can replace the lost program with other pipelines, the price may rebound on the cash runway strength.
Key entities
- companyNurix Therapeutics Inc.
Clinical‑stage biotech focused on targeted protein degradation.
- companySanofi
Pharmaceutical partner terminating the SAR448272 program.
